VITL Form 4: CMO McKeon uses 10b5-1 plan to sell shares after option exercise
Rhea-AI Filing Summary
Kathryn McKeon, CMO and GM, Butter at Vital Farms (VITL), reported scheduled insider transactions in August 2025. On 08/15/2025 she sold 12,005 shares under a Rule 10b5-1 plan at a weighted average price of $47.59, reducing her beneficial holdings to 37,513 shares. On 08/18/2025 she exercised and acquired 21,442 shares under an employee stock option with a $15.31 exercise price and simultaneously sold 21,442 shares at a weighted average price of $49.08. After these transactions she beneficially owns 58,955 shares (direct). The Form 4 discloses the 10b5-1 plan was adopted on May 16, 2025, and the option vests in three equal annual installments starting 03/13/2024.
Positive
- Use of a Rule 10b5-1 plan adopted May 16, 2025, indicates pre-established, compliant trading procedures
- Option exercise at $15.31 allowed acquisition of 21,442 shares, converting compensation into equity
- Sales executed under 10b5-1 reduce potential signaling risk because trades were pre-planned
Negative
- Insider sold a total of 33,447 shares (12,005 on 08/15/2025 and 21,442 on 08/18/2025), which reduced direct holdings to 37,513 before the option exercise
- Multiple sales at high prices (weighted averages $47.59 and $49.08) represent significant monetization by an executive
Insights
TL;DR: Insider executed option exercise and contemporaneous sales under a 10b5-1 plan, net holdings increased by option exercise then partially monetized.
The transactions are routine for executives exercising vested compensation and using a pre-established 10b5-1 plan to sell shares. The exercise price of $15.31 versus sale prices near $49 indicates a substantial spread between exercise cost and sale proceeds for those optioned shares, but the sales were pre-planned which reduces informational significance. The reported post-transaction beneficial ownership of 58,955 shares should be monitored against total shares outstanding for materiality assessment.
TL;DR: Governance signals are standard: use of a documented 10b5-1 plan and attorney-in-fact signature ensure procedural compliance.
The filing documents adoption of a Rule 10b5-1 trading plan and shows sales executed pursuant to that plan, which helps the issuer and insider demonstrate compliance with insider trading rules. The presence of an attorney-in-fact signature is consistent with delegated filing practices. No departures from typical disclosure or vesting terms are evident in the Form 4.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 21,442 | $0.00 | -- |
| Exercise | Common Stock | 21,442 | $15.31 | $328K |
| Sale | Common Stock | 21,442 | $49.08 | $1.05M |
| Sale | Common Stock | 12,005 | $47.59 | $571K |
Footnotes (1)
- These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.21 to $47.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.27 inclusive. The option vests in three equal annual installments commencing on March 13, 2024, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
